MacroGenics updates pipeline progress in third-quarter 2026 report
The company completed Phase 1 dose escalation for MGC028 and dosed its first patient with MGC030, while cash climbed to $287.7 million.
MacroGenics reported financial results for the quarter ended September 30, 2026, on November 12, alongside several pipeline updates.
For MGC028, an antibody-drug conjugate targeting ADAM9, the company said Phase 1 dose escalation has been completed, and the company has selected a lead indication, with plans to start a randomized evaluation of two dose levels in that indication by year end 2026.1 As of an October 10, 2026 data cutoff, there were no dose-limiting toxicities, and no cases of ILD or ocular toxicity were reported.1 The company said it plans to share an interim clinical update on the lead indication, covering both efficacy and safety, sometime in the first half of 2027.1
For MGC026, a B7-H3-targeted ADC, interim Phase 1 results were reported at the ESMO 2026 Congress, including encouraging efficacy data and a manageable safety and tolerability profile in heavily pretreated SCCHN patients.1 The company said it expects to finish enrolling the ongoing Simon two-stage monotherapy cohort of 40 SCCHN patients by the end of 2026, with an updated data readout expected around the middle of 2027.
The company also dosed its first patient in a Phase 1 study of MGC030, a novel ADC aimed at an undisclosed target, following IND clearance, enrolling patients across several advanced solid tumor types including urothelial, colorectal, gastric/GEJ, esophageal and pancreatic cancers.
On lorigerlimab, a PD-1 x CTLA-4 bispecific, interim Phase 2 results reported at ESMO 2026 showed encouraging preliminary clinical activity with single-agent dosing at 6 mg/kg every three weeks in clear cell gynecologic cancer.1 The company expects to complete enrollment of 20 CCGC patients at a lower 3 mg/kg dose by year end 2026, with updated results expected in the first half of 2027.1
On the corporate side, Gilead Sciences exercised an option in August to license a preclinical bispecific program under the companies' 2022 collaboration agreement, triggering a $10.0 million payment to MacroGenics.1
Cash, cash equivalents and marketable securities stood at $287.7 million as of September 30, 2026, compared to $189.9 million as of December 31, 2025.1 The company said this position, along with projected and anticipated future payments from partners, will support its cash runway through 2028.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.